HER2 PET
HER2 PET is a PET scan using radiolabelled trastuzumab or smaller HER2 binders to map HER2 across all metastases at once.
89Zr-trastuzumab and 68Ga/18F-labelled HER2 affibodies and nanobodies (e.g., 68Ga-ABY-025, 18F-GE-226) have been studied in the ZEPHIR and IMPACT trials. Predictive of T-DM1 response and useful for heterogeneous HER2-low disease where a single biopsy is unrepresentative. Not yet approved.
How it works
Radiolabelled HER2 binder; whole-body receptor map.
- Captures inter-lesion heterogeneity
- Non-invasive re-assessment
- Not approved; small trials
- Antibody tracers need days
Latest papers
topQuery for this technology: (TITLE:"HER2 PET" OR ABSTRACT:"HER2 PET" OR TITLE:"89Zr-trastuzumab" OR ABSTRACT:"89Zr-trastuzumab" OR TITLE:"HER2 imaging PET" OR ABSTRACT:"HER2 imaging PET"). Results are unfiltered search hits about HER2 PET, not a curated reading list.
Pages like this
not linked directly; found by shared links- TechnologyTROP2 PET
Shares Shaoli Song, Molecular imaging roadmap: FDG → PSMA → FAP → antigen and immune PET, Immuno-PET, PET (positron emission tomography).
- CompanyRefleXion Medical
Shares Molecular imaging roadmap: FDG → PSMA → FAP → antigen and immune PET, PET (positron emission tomography).
- TechnologyPET/MRI
Shares Molecular imaging roadmap: FDG → PSMA → FAP → antigen and immune PET, PET (positron emission tomography).
- ProductTrastuzumab biosimilars
Shares HER2, HER2-positive breast cancer, Gastric & gastro-oesophageal junction cancer.
- TargetGRPR (gastrin-releasing peptide receptor)
Shares PET (positron emission tomography), HR-positive / HER2-negative breast cancer.
- InstitutionInstituto Alexander Fleming
Shares HER2, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
- InstitutionOlivia Newton-John Cancer Wellness and Research Centre
Shares Immuno-PET, Gastric & gastro-oesophageal junction cancer.
- TechnologyPARP PET
Shares Molecular imaging roadmap: FDG → PSMA → FAP → antigen and immune PET, PET (positron emission tomography).